<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479346</url>
  </required_header>
  <id_info>
    <org_study_id>ISEE_2017_GGT</org_study_id>
    <nct_id>NCT03479346</nct_id>
  </id_info>
  <brief_title>Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With or Without Metabolic Syndrome Risk Factors - A Study Protocol for a Double-blind, Randomised, Multi-center, Placebo-controlled Clinical Trial</brief_title>
  <official_title>Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With or Without Metabolic Syndrome Risk Factors - A Study Protocol for a Double-blind, Randomised, Multi-center, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Oriental Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonkwang University Guangju Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongsin University Oriental Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gachon University Gil Oriental Medical Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this trial is to investigate the efficacy and safety of GGT on Korean obese&#xD;
      Women with or without metabolic syndrome Risk factors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2018</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in body weight</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Estimated mean changes from baseline in body weight after 12 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in body fat percentage</measure>
    <time_frame>baseline, 4,8,12 weeks</time_frame>
    <description>Estimated mean changes from baseline in body fat percentage at different time points during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in fat mass</measure>
    <time_frame>baseline, 4,8,12 weeks</time_frame>
    <description>Estimated mean changes from baseline in fat mass at different time points during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Waist circumference</measure>
    <time_frame>baseline, 4,8,12 weeks</time_frame>
    <description>Estimated mean changes from baseline in Waist circumference at different time points during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Waist/hip ratio</measure>
    <time_frame>baseline, 4,8,12 weeks</time_frame>
    <description>Estimated mean changes from baseline in Waist/hip ratio at different time points during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Body mass index</measure>
    <time_frame>baseline, 4,8,12 weeks</time_frame>
    <description>Estimated mean changes from baseline in Body mass index at different time points during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Lipid profile</measure>
    <time_frame>Screening visit, 12 weeks</time_frame>
    <description>Estimated mean changes from first visit in Lipid profile after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in C-reactive protein (CRP)</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Estimated mean changes from baseline in C-reactive protein (CRP) after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood glucose</measure>
    <time_frame>Screening visit, 12 weeks</time_frame>
    <description>Estimated mean changes from first visit in blood glucose after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of life 5 Dimension(EQ5D)</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>EQ-5D is a tool developed for health-related quality of life (HRQoL) assessment, and is widely used in the health care sector. Scores range from -1, 'health worse than death' to 1, 'perfect health'. EQ-5D-5L has 5 dimensions covering current health status and functionality: mobility (M), self care (SC), usual activities (UA), pain/discomfort (PD), and anxiety/depression (AD), to be rated out of 5 grades (1, no problem; 2, slight problem; 3, some/moderate problem; 4, severe problem; 5, extreme problem).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in serum leptin</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Estimated mean changes from first visit in serum leptin after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Korean version of Western Ontario and McMasters Universities Oateoarthritis Index</measure>
    <time_frame>baseline, 12, 16 weeks</time_frame>
    <description>Determination of patient's knee function and pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost per QALY(Quality Adjusted Life Years) gained</measure>
    <time_frame>6 months or 1 year</time_frame>
    <description>The cost per QALY gained is calculated according to normal health-economic evaluation models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation (medical costs)</measure>
    <time_frame>baseline, 4,8,12,16,20,24 weeks</time_frame>
    <description>Economic evaluation of medical costs will be performed to assess cost-effectiveness of the 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation (time-related costs)</measure>
    <time_frame>baseline, 4,8,12,16,20,24 weeks</time_frame>
    <description>Economic evaluation of time-related costs will be performed to assess cost-effectiveness of the 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation (lost productivity costs)</measure>
    <time_frame>baseline, 4,8,12,16,20,24 weeks</time_frame>
    <description>Economic evaluation of lost productivity costs will be performed to assess cost-effectiveness of the 2 groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes from baseline in Kellgren-Lawrence grade</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Determination of patient's knee condition</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>GGT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM &amp; FOODS Co. Ltd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM &amp; FOODS Co. Ltd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GGT</intervention_name>
    <description>Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM &amp; FOODS Co. Ltd.</description>
    <arm_group_label>GGT group</arm_group_label>
    <other_name>Galgeun-tang</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM &amp; FOODS Co. Ltd.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female aged 19 to 65 years&#xD;
&#xD;
               -  Subject must included at least one or more of the following symptoms below;&#xD;
&#xD;
                    -  BMI of 30 kg/㎡ or more;&#xD;
&#xD;
                    -  BMI between 27 and 29.9kg/㎡ with non-insulin-dependent diabetes mellitus,&#xD;
                       taking medication or fasting blood glucose &gt; 126mg/dL at the screening visit&#xD;
&#xD;
                    -  BMI between 27 and 29.9kg/㎡ with hyperlipidemia, taking medication or total&#xD;
                       cholesterol ≥ 200mg/dL or Triglyceride ≥ 150mg/dL at screening visit&#xD;
&#xD;
          -  Agreed to low-calorie diet during the trial&#xD;
&#xD;
          -  Written informed consent of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who had experience with allergic reaction on investigational drug(any&#xD;
             ingredients of IP)&#xD;
&#xD;
               -  Subjects who has diabetes as comorbidity, had experienced the elevation of blood&#xD;
                  glucose by ephedrine&#xD;
&#xD;
               -  Subjects who had experienced rash, rubefaction, or itchiness by GGT&#xD;
                  administration&#xD;
&#xD;
               -  Subjects who usually feel fatigue due to hyperhidrosis&#xD;
&#xD;
               -  Subjects who experienced other allergic reactions&#xD;
&#xD;
          -  Subjects who had 10 percent reduction in body weight over 6 months&#xD;
&#xD;
          -  Subjects who decided to quit smoking over the last 3 months or have irregular smoking&#xD;
             habits&#xD;
&#xD;
          -  Subjects who have endocrine diseases associated with weight gain, such as&#xD;
             hypothyroidism, Cushing's syndrome, etc.&#xD;
&#xD;
          -  Subjects who have heart disease (heart failure, angina pectoris, myocardial&#xD;
             infarction)&#xD;
&#xD;
          -  Subjects who have uncontrolled hypertension despite the use of antihypertensive drugs&#xD;
             (SBP &gt; 145 mmHg or DBP &gt; 95 mmHg)&#xD;
&#xD;
          -  Subjects who have uncontrolled diabetes despite the use of drugs (FBS&gt;7.8 mmol/L (140&#xD;
             mg/dL))&#xD;
&#xD;
          -  Subjects who have severe renal disability (SCr &gt; 2.0 mg/dL)&#xD;
&#xD;
          -  Subjects who have severe liver disability (2.5 fold of normal high range value on&#xD;
             Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase&#xD;
             [ALP])&#xD;
&#xD;
          -  Subjects who have poor digestion(anorexia, stomach discomfort, nausea, vomiting etc)&#xD;
             or have the history of eating disorder such as anorexia nervosa or bulimia nervosa,&#xD;
             etc.(KEAT-26 &lt; 20)&#xD;
&#xD;
          -  Use of medication that can affect on weight within last 3 months (appetite&#xD;
             suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine,&#xD;
             phenothiazine or medications can affect on absorption, metabolism, excretion)&#xD;
&#xD;
          -  Use of CNS stimulant medication for weight loss&#xD;
&#xD;
          -  Subjects who had a use of drugs that can increase blood pressure or heart rate within&#xD;
             a week, such as, Decongestants, cough, cold, allergy treatments that include the&#xD;
             ingredients of phenylpropanolamine, ephedrine, pseudoephedrine&#xD;
&#xD;
          -  Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent,&#xD;
             barbiturate, antipsychotic, medication concerns of abuse)&#xD;
&#xD;
          -  Subjects who have diseases that may occur hypokalemia (hypomagnesemia, Bartter&#xD;
             syndrome, Gitelman syndrome, diseases that can cause high aldosteronism etc.) or have&#xD;
             cardiac dysrhythmia&#xD;
&#xD;
          -  Difficult to measure anthropometric dimensions because of anatomical change such as&#xD;
             resection&#xD;
&#xD;
          -  History of weight loss surgery, such as bariatric surgery, etc.&#xD;
&#xD;
          -  Edema or dysuria&#xD;
&#xD;
          -  Malignant tumour or lung disease&#xD;
&#xD;
          -  Cholelithiasis&#xD;
&#xD;
          -  History of narrow angle glaucoma&#xD;
&#xD;
          -  Subjects who have nervous or psychological medical history or presently suffer from&#xD;
             the following diseases: depression, manic disorder, bipolar disorder, schizophrenia,&#xD;
             epilepsy, alcoholism, anorexia, hyperphagia, etc.&#xD;
&#xD;
          -  Subjects who have history of stroke or temporary ischemic cardioplegia&#xD;
&#xD;
          -  Subjects who are judged to be inappropriate for the clinical study by the researchers&#xD;
&#xD;
          -  Women who were pregnant, lactating or have the chances of pregnancy who do not agree&#xD;
             to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom,&#xD;
             abstinence, etc.)&#xD;
&#xD;
          -  Use of other investigational product within last 1 month&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun-Kyung Song, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Oriental Medical Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gachon University Gil Oriental Medical Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Oriental Medical Hospital</investigator_affiliation>
    <investigator_full_name>Yun-Kyung Song</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Traditional Korean Medicine</keyword>
  <keyword>Galgeun-tang</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

